Update 1st July 2022
The latest update on the Natpar shortages from Takeda are as follows:
- 100mcg dose – shortage duration is now unknown but is expected to last at least 6 months.
75mcg dose – shortage expected later in 2022
In response to your questions we can now tell you that :
- MHRA have sent information regarding latest treatment management to healthcare professionals (HCPs). Ask your endocrinologist about this if you haven’t already spoken to them.
- Existing patients will have priority regarding continued access to Natpar. However, Takeda will support new patients if their endocrinologist considers it necessary.
- Supply of Natpar in the USA and Europe are linked to manufacturing issues but for different reasons. In the USA there was a problem with rubber particles and in Europe the issue is with protein particles. However, ongoing rigorous testing ensures that current doses are safe.
We will keep you informed of any further updates.
30th May 2022
We are very sorry to tell you that Takeda have just informed us of shortages of the 100mcg dose of Natpar from late June/early July due to a manufacturer supply issue. This will affect UK, Europe and Canada. They expect to get this fixed within 6 months. The 75mcg dose will also be affected from September. The 50mcg and 25mcg doses are not affected. Endocrinologists will be informed by letter this week so please contact your doctor to discuss future plans and place orders now. We will keep you informed of any further updates.